BPMC News and Press, Blueprint Medicines Corporation From 08/01/22

Blueprint Medicines  ( NASDAQ: BPMC ) is scheduled to announce Q2 earnings results on Tuesday, August 2nd, before market open. The consensus EPS Estimate is -$2.26 (-21.5% Y/Y) and the consensus Revenue Estimate is $37.61M (+37.8% Y/Y). Over the last 1 year, BPMC ...

Blueprint Medicines to Report Second Quarter 2022 Financial Results on Tuesday, August 2, 2022 PR Newswire CAMBRIDGE, Mass. , July 26, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference ...

Raymond James updated its list of analyst favorite stocks with a swap in the restaurant subsector. Analysts can only have one favorite idea among the stocks they cover rated Strong Buy or Outperform. Ruth's Hospitality Group ( NASDAQ: RUTH ) makes it onto the Analysts Cu...

Qiming Venture Partners closed two new China healthcare and technology funds with $3.2 billion in fresh capital, both of them at their hard cap limits. Suzhou CStone Pharma announced that Gavreto® (pralsetinib) was approved in Hong Kong to treat adult patients with RET fusion-pos...

Blueprint Medicines Publishes Inaugural Corporate Responsibility Report PR Newswire -- Report highlights efforts to deliver sustainable value to patients and communities, foster a diverse and empowered workforce, and operate with exceptional integrity -- CAMB...

Blueprint Medicines ( NASDAQ: BPMC ) said it signed strategic financing collaborations with Sixth Street and Royalty Pharma ( NASDAQ: RPRX ) for up to $1.25B. Blueprint is selling royalty rights on lung cancer drug Gavreto — marketed by Roche ȁ...

Attractive, precision oncology therapy with long patent duration added to portfolio Blueprint Medicines to receive $175 million upfront and $165 million in potential milestone payments NEW YORK, June 30, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today an...

Blueprint Medicines Announces Transformative $1.25 Billion Strategic Financing Collaborations with Sixth Street and Royalty Pharma PR Newswire Strengthens balance sheet with significant non-dilutive, low-cost capital Expands ability to bring the promise of pr...

The precision therapy company Blueprint Medicines (NASDAQ:BPMC) is trading lower in the morning hours Monday after Wells Fargo launched its coverage with an Underweight recommendation citing, among other things, a “sell the news” data readout this year. Blueprint (BPMC) plans to...

Blueprint Medicines Appoints Habib Dable to its Board of Directors PR Newswire CAMBRIDGE, Mass. , June 23, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of Habib Dable to its board of directors. Mr...